An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease Benjamin Ungar, Sandra Garcet, Juana Gonzalez, Nikhil.

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

Petrolatum: Barrier repair and antimicrobial responses underlying this “inert” moisturizer Tali Czarnowicki, MD, Dana Malajian, BA, Saakshi Khattri, MD,

Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology Saakshi Khattri, MD, Avner.

Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence Mariya Rozenblit, BA, Mayte Suarez-Farinas,

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study Robert Bissonnette, François Harel,

RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications Mayte.

An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis Amy S. Paller, MD, MS, Yael Renert-Yuval, MD, Maria Suprun, MPH,

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.

As in Atopic Dermatitis, Nonlesional Skin in Allergic Contact Dermatitis Displays Abnormalities in Barrier Function and Ceramide Content Donghye Kim,

Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis Mayte Suárez-Fariñas, PhD,

Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,

Jack L. Arbiser, Michael Y. Bonner

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,

Jay-Hyun Jo, Elizabeth A. Kennedy, Heidi H. Kong

Expanding Our Understanding of Human Skin Aging

An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease Benjamin Ungar, Sandra Garcet, Juana Gonzalez, Nikhil.

Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis Tali Czarnowicki, MD, Dana Malajian, BA, Avner Shemer,

Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response Suzanne Tintle, BS, Avner Shemer, MD, Mayte Suárez-Fariñas,

Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing.

Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling David A. Ewald, MSc, Shinji.

TREM-1 as a Potential Therapeutic Target in Psoriasis

IL-22–producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17–producing TH17 T cells Kristine E. Nograles, MD,

Longitudinal Evaluation of the Skin Microbiome and Association with Microenvironment and Treatment in Canine Atopic Dermatitis Charles W. Bradley, Daniel.

Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing Mayte Suárez-Fariñas, PhD, Benjamin Ungar,

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study Robert Bissonnette, François Harel,

Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures Huei-Chi.

An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation Teresa Song, BS, Ana B. Pavel, PhD, Huei-Chi Wen, MD, PhD,

Clinical Snippets Journal of Investigative Dermatology

Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene.

IL-36γ (IL-1F9) Is a Biomarker for Psoriasis Skin Lesions

Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept.

Antonio Julià Journal of Investigative Dermatology

Serum Autotaxin Levels Correlate with Pruritus in Patients with Atopic Dermatitis Momoko Nakao, Makoto Sugaya, Hiraku Suga, Makiko Kawaguchi, Sohshi Morimura,

PXR: A New Player in Atopic Dermatitis

Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism Emma Guttman-Yassky, MD, PhD, Benjamin Ungar, BA, Shinji Noda, MD, PhD, Maria.

Molecular Profiling of Immune Activation Associated with Regression of Melanoma Metastases Induced by Diphencyprone Nicholas Gulati, Sandra Garcet, Judilyn.

Cellular Genomic Maps Help Dissect Pathology in Human Skin Disease

Research Techniques Made Simple: Cost-Effectiveness Analysis

Modeling Atopic Dermatitis with Increasingly Complex Mouse Models

Shrinking the Psoriasis Assessment Gap: Early Gene-Expression Profiling Accurately Predicts Response to Long-Term Treatment Joel Correa da Rosa, Jaehwan.

Early Activation of Th2/Th22 Inflammatory and Pruritogenic Pathways in Acute Canine Atopic Dermatitis Skin Lesions Thierry Olivry, David Mayhew, Judy.

Effective Narrow-Band UVB Radiation Therapy Suppresses the IL-23/IL-17 Axis in Normalized Psoriasis Plaques Leanne M. Johnson-Huang, Mayte Suárez-Fariñas,

Anjali Shroff, MD, Emma Guttman-Yassky, MD, PhD JAAD Case Reports

The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory.

Tamar Nijsten Journal of Investigative Dermatology

Nikhil Dhingra, Emma Guttman-Yassky

Epidemiology of Eczema Herpeticum in Hospitalized U. S

More Than Many: How to Manage the Most Frequent Cancer?

Decreased Levels of Sphingosine, a Natural Antimicrobial Agent, may be Associated with Vulnerability of the Stratum Corneum from Patients with Atopic.

Journal of Allergy and Clinical Immunology

Efficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis Chloé Théréné, Emilie Brenaut, Thomas Barnetche,

Mayte Suárez-Fariñas, Judilyn Fuentes-Duculan, Michelle A

Sigrun A.J. Schmidt, Serigne Lo, Loes M. Hollestein

Journal of Investigative Dermatology

High-Density Lipoprotein Cholesterol Function Improves after Successful Treatment of Psoriasis: A Step Forward in the Right Direction Nehal N. Mehta,

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,

Michael C. Velarde Journal of Investigative Dermatology

Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis Andrea Chiricozzi, Emma.

Transcriptional Profiling of Psoriasis Using RNA-seq Reveals Previously Unidentified Differentially Expressed Genes Ali Jabbari, Mayte Suárez-Fariñas,

Journal of Investigative Dermatology

Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects TH17 pathway differences between these diseases Nikhil Dhingra, BS, Mayte.

Erratum Journal of Investigative Dermatology

A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis Eric L. Simpson, Shinichi Imafuku, Yves Poulin, Benjamin Ungar, Lisa Zhou,

Petrolatum: Barrier repair and antimicrobial responses underlying this “inert” moisturizer Tali Czarnowicki, MD, Dana Malajian, BA, Saakshi Khattri, MD,

Journal of Investigative Dermatology

Volume 79, Issue 5, Pages (March 2011)

Conceptual Issues in Measuring the Burden of Skin Diseases

Journal of Investigative Dermatology

Journal of Investigative Dermatology

Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2/TH1 cell imbalance, whereas adults acquire CLA+ TH22/TC22 cell.

Presentation transcript:

An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease Benjamin Ungar, Sandra Garcet, Juana Gonzalez, Nikhil Dhingra, Joel Correa da Rosa, Avner Shemer, James G. Krueger, Mayte Suarez-Farinas, Emma Guttman-Yassky Journal of Investigative Dermatology Volume 137, Issue 3, Pages 603-613 (March 2017) DOI: 10.1016/j.jid.2016.09.037 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Atopic dermatitis (AD) serum cytokines and chemokines before and after cyclosporine A (CsA) treatment. Relative levels of AD serum markers (in log2 fold change [FCH]) (a) at baseline (vs. healthy control subjects) and (b) after CsA treatment. Mean ± standard error of the mean. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. Journal of Investigative Dermatology 2017 137, 603-613DOI: (10.1016/j.jid.2016.09.037) Copyright © 2016 The Authors Terms and Conditions

Figure 2 Serum versus skin levels of cytokines and chemokines. Scatterplot of the highest correlation between cytokines or chemokines in serum versus (a) levels of baseline lesional (LS) skin, (b) baseline nonlesional (NL) skin, and (c) NL skin after cyclosporine A (CsA) treatment. Regression lines in blue, with gray smoothed confidence interval. Journal of Investigative Dermatology 2017 137, 603-613DOI: (10.1016/j.jid.2016.09.037) Copyright © 2016 The Authors Terms and Conditions

Figure 3 μScore models of baseline biomarker correlations with SCORAD. Representative top multivariate correlation models of SCORAD with baseline biomarkers in (a) lesional (LS) skin with (b) associated scatterplots, (c) nonlesional (NL) skin (d) with associated scatterplots, and (e) LS + NL + serum (f) with associated scatterplots. Regression lines in blue, with gray smoothed confidence interval. SCORAD, Scoring of AD; val, value. Journal of Investigative Dermatology 2017 137, 603-613DOI: (10.1016/j.jid.2016.09.037) Copyright © 2016 The Authors Terms and Conditions

Figure 4 μScore models of therapeutic response biomarker correlations with SCORAD. Representative top multivariate correlation models of SCORAD with therapeutic response biomarkers in (a) lesional (LS) skin (b) with associated scatterplots, (c) nonlesional (NL) skin (d) with associated scatterplots, and (e) LS + NL + serum (f) with associated scatterplots. Regression lines in blue, with gray smoothed confidence intervals. SCORAD, Scoring of AD; val, value. Journal of Investigative Dermatology 2017 137, 603-613DOI: (10.1016/j.jid.2016.09.037) Copyright © 2016 The Authors Terms and Conditions

Figure 5 μScore models of biomarker correlations with HistScore. Representative top multivariate correlation models of HistScore with biomarkers in (a) lesional (LS) + nonlesional (NL) + serum at baseline (b) with associated scatterplots, (c) therapeutic response biomarkers in LS skin (d) with associated scatterplots, and (e) therapeutic response biomarkers in LS + NL + serum (f) with associated scatterplots. Regression lines in blue, with gray smoothed confidence intervals. val, value. Journal of Investigative Dermatology 2017 137, 603-613DOI: (10.1016/j.jid.2016.09.037) Copyright © 2016 The Authors Terms and Conditions